August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
March 2026 in “International Journal of Biological Macromolecules” Recombinant Filaggrin-2 microneedles effectively promote hair growth and repair in hair loss.
May 2026 in “Journal of Human Immunity” Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
April 2023 in “Journal of Investigative Dermatology” The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.
49 citations
,
April 1997 in “Human reproduction” Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
2 citations
,
February 2023 in “F&S Reports” Elagolix did not effectively treat polycystic ovary syndrome.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
18 citations
,
June 2020 in “Dermatologic Therapy” FCO2 laser is a better treatment for alopecia areata than intralesional steroids.
September 2016 in “Journal of Dermatological Science” Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.
October 2024 in “International Journal of Medical Arts” Corticosteroids regrow hair better and faster than pentoxifylline for alopecia areata.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
Fractional CO2 laser is more effective and safer than steroid injections for treating alopecia areata.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
December 2024 in “Kufa Medical journal” Higher levels of IL-17A and IL-2 are linked to alopecia areata.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
16 citations
,
January 2020 in “Annals of the rheumatic diseases” Baricitinib might help treat hair loss in lupus patients, but more research is needed.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
April 2018 in “Journal of Investigative Dermatology” Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.
42 citations
,
December 1976 in “PubMed” Cyproterone acetate and ethinylestradiol effectively reduce hirsutism and acne in women.